Trial Profile

Phase 2a/b study of KVA12123 in mutated NPM1 r/r acute myeloid leukemia patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2025 According to TuHURA Biosciences media release, a mini KOL symposium held on December 5, 2025, prior to the ASH meeting, provided valuable scientific rational for targeting VISTA in AML and recommendations on our Phase 2 clinical trial plans for TBS-2025, in AML.
14 Nov 2025 According to TuHURA Biosciences media release, company plans to initiate this Phase 2 randomized study in the first quarter of 2026.
30 Jun 2025 According to TuHURA Biosciences media release, TuHURA Biosciences has acquired Kineta. TuHURA is planning to initiate this Phase 2 randomized trial of KVA1213 in combination with a menin inhibitor in NPM1 mutated AML in 2H 2025. The molecule KVA1213 is now renamed as TBS-2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com